Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)
National Institutes of Health
About this archived opportunity
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit competitive revision (formerly known as competitive supplement) applications from awardees with active U19 awards funded under RFA-RM-22-015 as part ofthe NIH Somatic Cell Genome Editing program, in order to expand the scope of the original award to allow first in human genome editing clinical trials using the therapeutic clinical candidates developed through the U19 award. RFA-RM-22-015 did not allow a clinical trial, whereas the present NOFO (RFA-RM-24-008) requires a clinical trial.
Historical details
- Status
- Closed
- Deadline
- February 13, 2026
- First captured
- December 17, 2025
- Publisher reference
- 357306
Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
This opportunity has closed
Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)
by National Institutes of Health
Get notified when similar opportunities open
We'll save this search and email you when new competition, competing, revisions opportunities are posted. Free.